Sugi Predict

Sugi Predict / Compounds / SCHEMBL6379461

SCHEMBL6379461

SCHEMBL6379461

OCC(Cl)COCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 4/20 0.53
▸ CA2 P00918 2/20 0.53
▸ CA7 P43166 2/20 0.53
▸ CA9 Q16790 2/20 0.53
▸ TSHR P16473 1/20 0.52
▸ TACR1 P25103 2/20 0.47
▸ SLC1A1 P43005 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ POLB P06746 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ CYP1A2 P05177 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ AGER Q15109 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23674403 1.00 CA1 (0.53) CA1CA2CA7CA9TSHR
SCHEMBL17789130 0.81 TSHR (0.52) CA1CA2CA7CA9TSHR
SCHEMBL10744312 0.81 TSHR (0.52) CA1CA2CA7CA9TSHR
SCHEMBL3665423 0.81 TSHR (0.52) CA1CA2CA7CA9TSHR
SCHEMBL14453897 0.80 CA1 (0.56) CA1CA2CA7CA9TSHR
SCHEMBL1865158 0.80 CA1 (0.56) CA1CA2CA7CA9TSHR
SCHEMBL19496903 0.80 CA1 (0.61) CA1CA2CA7CA9TSHR
SCHEMBL24215416 0.79 TSHR (0.50) CA1CA2CA7CA9TSHR
SCHEMBL24215413 0.79 TSHR (0.50) CA1CA2CA7CA9TSHR
SCHEMBL122306 0.78 CA1 (0.70) CA1CA2CA7CA9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12617802-B2 Sulfonimidamide compounds as NLRP3 modulators GENENTECH, INC. (US) 2026-05-05 — — US disclosed
US-20240336625-A1 SULFONIMIDAMDE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2024-10-10 — — US disclosed
EP-4373826-A1 SULFONIMIDAMDE COMPOUNDS AND USES THEREOF Genentech, Inc. (US) 2024-05-29 — — EP disclosed
CN-117677622-A Sulfonyl imide amide compounds and uses thereof 基因泰克公司 2024-03-08 — — CN disclosed
US-20230159555-A1 SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS GENENTECH, INC. (US) 2023-05-25 — — US disclosed
US-20230159555-A1 SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS GENENTECH, INC. (US) 2023-05-25 — — US disclosed
US-20230159555-A1 SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS GENENTECH, INC. (US) 2023-05-25 — — US disclosed
WO-2023004257-A1 SULFONIMIDAMDE COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2023-01-26 — — WO disclosed
CN-115461120-A Sulfonylimide compounds as NLRP3 modulators 豪夫迈·罗氏有限公司 2022-12-09 — — CN disclosed
EP-4093509-A1 SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS F. Hoffmann-La Roche AG (CH) 2022-11-30 — — EP disclosed
EP-0882050-B2 PROCESS FOR PREPARING PURINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2005-05-04 — — EP disclosed
EP-0882050-B1 PROCESS FOR PREPARING PURINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2002-08-28 — — EP disclosed
US-6340756-B1 VIRICIDES SYNTEX (U.S.A.) INC. 2002-01-22 — — US disclosed
CN-1064683-C Process for preparing purine derivatives HOFFMANN LA ROCHE (CH) 2001-04-18 — — CN disclosed
US-6218568-B1 REACTING 1-ARALKYLOXY-3-HALO-2-PROPANOL WITH METHOXYMETHYL ALKANOATE IN APROTIC SOLVENT IN THE PRESENCE OF A CATALYST TO PRODUCE 1-ARALKYLOXY-3-HALO-2-(ALKANOYLOXY)METHOXYPROPANE AND TREATING THE PRODUCT WITH ALKALI METAL ALKANOATE SYNTEX (U.S.A.) INC. 2001-04-17 — — US disclosed
US-6215017-B1 1-ARALKYLOXY-3-ACYLOXY-2-(ACYLOXY)METHOXYPROPANE DERIVATIVE; CHEMICAL INTERMEDIATES FOR VIRICIDE GANCICLOVIR SYNTEX (U.S.A.) INC. 2001-04-10 — — US disclosed
US-6040446-A Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative SYNTEX (U.S.A.) INC. (US) 2000-03-21 — — US disclosed
CN-1212693-A Process for preparing purine derivatives HOFFMANN LA ROCHE (CH) 1999-03-31 — — CN disclosed
EP-0882050-A1 PROCESS FOR PREPARING PURINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 1998-12-09 — — EP disclosed
WO-1997027198-A1 PROCESS FOR PREPARING PURINE DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 1997-07-31 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159555-A1 SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS NLRP3, NLRP1, PYCARD CA1 3982/4885CA2 3131/4885CA7 4508/4885
US-12617802-B2 Sulfonimidamide compounds as NLRP3 modulators NLRP3, NLRP1, PYCARD CA1 3114/4885CA2 1313/4885CA7 4090/4885
US-20240336625-A1 SULFONIMIDAMDE COMPOUNDS AND USES THEREOF NLRP3, PYCARD, NLRP1 CA1 3322/4885CA2 2034/4885CA7 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.